ポスト

Overlapping KM curves can sometimes be great news. In the phase 3 JBCRG-M06 trial, eribulin+HP had non-inferior PFS compared with taxane+HP in 1L HER2 MBC, with differentiated tox profile. New reasonable combination option in this setting. Congrats to the Japanese colleagues. https://t.co/WFVVe2IDf7

メニューを開く

Paolo Tarantino@PTarantinoMD

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ